Table 2 Characteristics of the studies included to assess the demographic characteristics, co-morbidities and clinical warning signs of severe dengue
From: Clinical predictors of severe dengue: a systematic review and meta-analysis
Parameters | Frequency (n) | Percentage (%) |
|---|---|---|
WHO Classification type | ||
 1997 | 58 | 40.6 |
 2009 | 85 | 59.4 |
WHO region | ||
 South-East Asia | 74 | 51.8 |
 Western Pacific | 33 | 23.1 |
 American | 26 | 18.2 |
 Eastern Mediterranean | 7 | 4.9 |
 European | 2 | 1.4 |
 Africa | 1 | 0.7 |
Study design | ||
 Case control | 26 | 18.2 |
 Cohort | 36 | 25.2 |
 Cross-sectional | 81 | 56.6 |
Study population | ||
 Children | 59 | 41.3 |
 Adults | 36 | 25.2 |
 Mixed | 47 | 32.9 |
 No information | 1 | 0.7 |
Recruitment year | ||
 1990–2010 | 78 | 54.6 |
 2011–2019 | 64 | 44.8 |
 No information | 1 | 0.7 |
Laboratory diagnosis | ||
 ELISA | 96 | 67.1 |
 PCR | 49 | 34.3 |
 RDT | 27 | 18.9 |
 HI | 10 | 7.0 |
 Viral culture | 4 | 2.8 |
 Immunohistochemistry | 2 | 1.4 |
 Immunofluorescence assay | 1 | 0.7 |
 Neutralization test | 1 | 0.7 |
 Dotblot immuno assay | 1 | 0.7 |
 No information | 13 | 9.1 |